Sartorius Stedim Biotech (DIM) Q3 2025 earnings summary

Executive summary

• Sales grew by 7.5% in constant currencies to €2.6 billion for the nine-month period, driven by strong recurring consumables demand and margin expansion to 29.7%, despite FX headwinds.

• Bioprocess Solutions (BPS) delivered double-digit growth in recurring business, offsetting softness in equipment, while Lab Products and Services (LPS) showed gradual improvement and stabilization.

• All regions contributed to growth, with the Americas and Asia-Pacific leading, and China stabilizing.

• Underlying net profit and EPS saw significant increases, with net profit after non-controlling interest up 68.5%.

• Management raised full-year guidance, expecting around 9% sales growth and a 31% underlying EBITDA margin.

Financial highlights

• Underlying EBITDA grew 12.8% to €774 million, with margin up 200 bps to 29.7%.

• Underlying EPS increased by 17% year-over-year; reported net profit up 66% to €125 million.

• Operating cash flow was €511 million, and free cash flow reached €200 million, both lower due to working capital and capex.

• Capital expenditures totaled €276 million, representing 12.6% of sales revenue.

• Gross profit for the nine months was €1,028.4 million, up from €890.4 million year-over-year.

Outlook and guidance

• Full-year 2025 group sales growth expected at around 7% in constant currencies; BPS at 9%, LPS roughly flat.

• Underlying EBITDA margin forecast slightly above 29.5% for the group, above 31.5% for BPS, and around 21.5% for LPS.

• CapEx ratio expected at 12.5–13% of sales; net debt/EBITDA to decrease to approximately 3.5x by year-end.

• For Sartorius Stedim Biotech, sales growth guidance upgraded to 9% in constant currencies, with EBITDA margin at 31%.

• Management raised full-year guidance to the upper end of the forecast range.